Areteia Therapeutics Granted ILAP Designation from UK MHRA for Oral Dexpramipexole for Eosinophilic Asthma
Areteia Therapeutics today announced that the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has granted an Innovation Passport under the Innovative Licensing and Access Pathway (ILAP) to dexpramipexole, an eosinophil lowering small molecule, that has recently entered Phase III clinical development.
The Innovation Passport is the first step in the ILAP process, triggering the MHRA and its partner agencies, including the National Institute for Health and Care Excellence (NICE), the Scottish Medicines Consortium (SMC) and National Health Service (NHS) England, to chart a roadmap for regulatory and development milestones with the goal of early patient access in the U.K.
“It is great to see that in granting an Innovation Passport, the MHRA is as excited as we are about the potential for dexpramipexole,” said Jorge Bartolome, Chief Executive Officer of Areteia Therapeutics. He added, “If approved, dexpramipexole would represent the first oral drug for eosinophilic asthma patients, offering an alternative to injectable biologics.”
About Dexpramipexole
Dexpramipexole inhibits the maturation and release of eosinophils in bone marrow, based on evidence from cell cultures and human biopsies, thereby lowering peripheral blood eosinophil levels. Most recently in a Phase II study (EXHALE-1) in patients with moderate-to-severe eosinophilic asthma, treatment with dexpramipexole resulted in a significant, dose-dependent reduction in blood absolute eosinophil count at all doses tested (dexpramipexole doses of 37.5 mg, 75 mg, or 150 mg twice daily) compared to placebo. Dexpramipexole was well tolerated in the trial, with adverse events balanced across treatment and placebo groups, no serious adverse events, and no adverse events leading to discontinuation.
About Areteia Therapeutics
Areteia Therapeutics (areteiatx.com) is a clinical stage biotechnology company committed to putting asthma patients in better control of their disease and lives by developing the first potential oral drug for eosinophilic asthma. Areteia’s lead drug candidate is dexpramipexole, a first-in-class oral eosinophil maturation inhibitor. Areteia was created by Population Health Partners and Knopp Biosciences. A syndicate of leading life sciences and strategic investors led by Bain Capital Life Sciences with participation from Access Biotechnology, GV, ARCH Venture Partners, Saturn Partners, Sanofi, Maverick Capital, and Population Health Partners, has committed to invest up to $350 million in Series A financing to establish Areteia and advance dexpramipexole through Phase 3 clinical trials, secure commercial supply, and pursue potential next-generation medicines. Areteia is conducting late-stage development including three Phase 3 clinical trials of dexpramipexole in partnership with Population Health Partners’ development unit, Validae Health.
About Eosinophilic Asthma
Asthma disrupts the lives of more than a quarter of a billion people worldwide. More than half of asthma patients have eosinophilic asthma, which is driven by an oversupply of eosinophils, a type of white blood cell, in blood and tissue. By inhibiting the maturation of eosinophils, oral dexpramipexole acts in a way similar to injectable anti-IL-5 biologic therapies. The asthma biologic market is experiencing growth of 10% per year and is valued at around $8 billion, with IL-5 biologic therapies representing greater than $3 billion of that figure. If approved as a first-to-market oral drug, dexpramipexole could provide a compelling alternative to injectable biologics, and could potentially be used earlier in the asthma treatment paradigm to prevent progression of disease.
About ILAP
The U.K. Medicines and Healthcare products Regulatory Agency (MHRA) launched ILAP at the start of 2021 in order to accelerate the development and access to promising medicines in the early stages of development. The pathway, part of the UK’s plan to attract life sciences development in the post-Brexit era, features enhanced input and interactions with MHRA and other stakeholders. Other benefits of ILAP include access to a range of development tools, such as the potential for a 150-day accelerated Marketing Authorization Application (MAA) assessment, rolling review and a continuous benefit risk assessment.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230223005103/en/
Contact information
Tamsin Berry Tamsin.Berry@areteiatx.com
Mark Kreston Mark.Kreston@areteiatx.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SLB OneSubsea and Subsea7 Sign Long-Term Strategic Collaboration Agreement with Equinor; Commence Work on Wisting and Bay Du Nord Projects2.5.2024 15:20:00 EEST | Press release
SLB (NYSE: SLB) has announced the signing of a new long-term strategic collaboration agreement between Equinor ASA and the Subsea Integration Alliance (which comprises OneSubsea™ and Subsea7). The agreement paves the way for exploratory work to begin on two projects: the Wisting field offshore Norway and Bay Du Nord, off Newfoundland and Labrador, Canada. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240501491687/en/ The strategic collaboration agreement enables early information sharing, technology innovation and other collaborative benefits critical to unlocking more subsea projects by making them economically viable. (Photo: Business Wire) The agreement, which was signed today in Stavanger, Norway, represents an innovative, integrated way of working. It enables early information sharing, technology innovation and other collaborative benefits critical to unlocking more subsea projects by making them economically viable. B
Parse Biosciences Launches Single Cell Immune Profiling Products2.5.2024 15:15:00 EEST | Press release
Parse Biosciences, a leading provider of accessible and scalable single cell sequencing solutions, today announced the availability of Evercode™ BCR and the expansion of its existing Evercode™ TCR product line. The new BCR solution and updates to the existing TCR product line expand Parse’s single cell portfolio and will enable researchers to study the immune repertoire at unprecedented resolution and scale. Evercode BCR allows researchers to capture B cell receptor (BCR) sequences together with gene expression from the same cells. While existing tools struggle to capture the immense diversity of the BCR repertoire, Evercode BCR offers a breakthrough by measuring paired BCR sequences (both heavy and light chains) in up to one million cells in a single experiment. This scalable approach enables assignment of BCR clonotypes to various B-cell subtypes and activation states, providing unprecedented resolution and unleashing new capabilities in antibody discovery. Parse has also expanded it
Lenovo Advances Focus on Customer Security with new AI-powered Cyber Resiliency as a Service2.5.2024 15:00:00 EEST | Press release
Lenovo (HKSE: 992) (ADR: LNVGY), the global technology powerhouse, has launched its new AI-based Cyber Resiliency as a Service (CRaaS) leveraging Lenovo device telemetry and the Microsoft security software portfolio including Microsoft Copilot for Security and Defender for Endpoint. With AI offering protection at multiple levels, the new solution integrates greater visibility with cyber protection, detection, response and recovery across digital estates and devices. This benefits customers by helping them operate more securely across devices, users, apps, data, networks, and cloud services and aids business continuity in the face of attacks. Security remains top-of-mind for business leaders due to various market and technology trends such as shift to hybrid work, increasing adoption of AI, and proliferation of data and devices In the third global annual survey of Chief Information Officers (CIOs) by Lenovo, 51% of CIOs said that cybersecurity remains a top priority for IT, and 65% said
Edgio Launches Attack Surface Management for Continuous Threat Protection2.5.2024 15:00:00 EEST | Press release
Edgio, the platform of choice for security, speed and simplicity at the edge, today announced the launch of its Attack Surface Management (ASM) solution. ASM is designed to discover all web assets, provide full inventory of technologies, detect security exposures and manage exposure response across an organization from a centralized management interface. ASM, coupled with Edgio’s holistic web security solutions and managed security services provide the industry’s first edge-enabled continuous web application threat management service. In an era where AI-driven threats are escalating at an unprecedented rate, it is crucial to deploy solutions that can keep pace with ever-evolving advanced persistence threats. Based on the findings from Verizon’s Data Breach Investigation Report (DBIR), over 60% of data breaches were attributed to web applications. Moreover, according to a 2023 report by IBM, the average cost of a data breach amounted to $4.45 million. These findings highlight the need f
Canadian hydropower producer upgrades timing network with Adtran’s Oscilloquartz optical cesium clock2.5.2024 15:00:00 EEST | Press release
Adtran today announced that a leading Canadian hydropower producer is using its Oscilloquartz grandmaster device combined with its optical cesium atomic clock to achieve new levels of precision, reliability and resilience in its power grid synchronization network. The deployment addresses the urgent need to implement the highest standards of protection against GNSS disruptions, including jamming and spoofing cyberattacks, and helps bolster North America’s energy resilience. Featuring multi-source protection, the enhanced timing architecture offers a zero-trust approach to positioning, navigation and timing (PNT), ensuring robust and accurate synchronization. It also seamlessly supports existing services, enabling a smooth transition from legacy timing to power grids with advanced PTP technology. For streamlined operations and assurance, the synchronization network is remotely managed through the Adtran Ensemble Controller with Sync Director. This press release features multimedia. View
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom